Re: Peregrine/Bavituximab, PCrutch, after reading/absorbing what Dr. Gerber said in his Sept7 ASCO/Thoracic/Chicago plenary talk ( http://tinyurl.com/8oxwk6v ) about Bavi doubling MOS vs. DoceCTL in Peregrine’s randomized 2nd-Line NSCLC n=121/2B trial with “no significant safety differences between the 3 treatment arms”, do you still believe that it's “criminal” that Peregrine is still giving Bavituximab to patients? …and a followup question: Did Dr. Gerber make you Smile Friday?